RobotMe summary
Warp Sciences announced on October 22 that it had raised $215 million and is building a U.S.-based chemistry contract research organization. The company plans to combine expert chemists, AI models, and laboratory robotics to produce and test compounds for biotech and pharmaceutical customers.
Its first service is lead-optimization analog synthesis, which makes variations of a molecule so a research team can compare their properties before selecting a drug candidate. Warp says its labs will use experimental results to improve its models and future automation. The company is supplying research services; it says it has no proprietary drug pipeline.
The funding, initial service, and intended use of robotics come from Warp’s announcement. The release does not provide customer names, laboratory throughput, or independently verified evidence that the approach shortens discovery timelines.